Amgen, Immunex deal

AMGN will acquire IMNX for $16 billion in stock and cash. The combined company is expected to post $1.5 billion in net income on $5.5 billion in revenues in 2002. The transaction, which will bring IMNX's marketed Enbrel arthritis drug under the same roof as AMGN's Epogen, Neupogen and Aranesp, a second generation Epogen, is expected to close near the middle of 2002. ...